Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer

This study has been completed.
Federation Francophone de Cancerologie Digestive
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: July 8, 2003
Last updated: September 20, 2012
Last verified: September 2012

RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving gemcitabine together with radiation therapy is more effective than gemcitabine alone following surgery in treating pancreatic cancer.

PURPOSE: This randomized phase II/III trial is studying how well giving gemcitabine together with radiation therapy works and compares it to gemcitabine alone in treating patients who have undergone surgery for pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy
Radiation: radiation therapy
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Feasibility of full completion of treatment as measured by the number of patients completing treatment 1 month after treatment in phase II [ Designated as safety issue: No ]
  • Tolerability in terms of acute toxicity as measured by NCI-CTC v2.0 1 month after completion of treatment in phase II [ Designated as safety issue: Yes ]
  • Tolerability in terms of late toxicity as measured by EORTC and RTOG 1 month after completion of treatment in phase II [ Designated as safety issue: Yes ]
  • Overall survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter in phase III [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Disease-free survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter [ Designated as safety issue: No ]
  • Acute toxicity as measured by NCI-CTC v2.0 every 3 months in years 1-2, and every 6 months thereafter [ Designated as safety issue: Yes ]
  • Late toxicity as measured by EORTC and RTOG every 3 months in years1-2, and every 6 months thereafter [ Designated as safety issue: Yes ]
  • Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) v3.0 and EORTC QLQ PAN-26 every 3 months in years 1-2 and every 6 months thereafter [ Designated as safety issue: No ]

Enrollment: 97
Study Start Date: May 2003
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Detailed Description:


Phase II:

  • Determine the feasibility of gemcitabine followed by chemoradiotherapy with gemcitabine vs gemcitabine alone after prior curative resection in patients with pancreatic head adenocarcinoma.
  • Compare the tolerability of these regimens, in terms of acute and late toxicity, in these patients.

Phase III:

  • Compare the disease-free and overall survival of patients treated with these regimens .
  • Compare the quality of life of patients treated with these regimens.
  • Compare the toxicity of these regimens in these patients.
  • Determine the sites of recurrence in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG/WHO performance status (0-1 vs 2), participating center, and N stage (N0 vs N1 vs NX). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Within 8 weeks after prior surgical resection, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses.

Patients then receive additional gemcitabine IV over 30 minutes on days 57, 64, 71, 78, 85, and 92. Beginning on day 57, patients also undergo radiotherapy once daily, 5 days a week, for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

  • Arm II: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for 4 courses.

Quality of life (QOL) is assessed in both arms, according to the following schedules:

  • Arm I: QOL is assessed at baseline; at 3 weeks after the beginning of chemoradiotherapy; after the completion of chemoradiotherapy; every 3 months for 2 years; and then every 6 months for 1 year.
  • Arm II: QOL is assessed at baseline; at 12 weeks; at 16 weeks; every 3 months for 2 years; and then every 6 months for 1 year.

Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 538 patients (269 per treatment arm) will be accrued for this study within 3 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed pancreatic head adenocarcinoma
  • Prior pancreaticoduodenectomy required

    • Documented histological examination of surgical margins (R0), including retroperitoneal margin
    • Performed within the past 8 weeks
  • Any number of lymph nodes (less than 10 OR 10 or more) allowed
  • No periampullary cancer



  • 18 and over

Performance status

  • ECOG 0-2 OR
  • WHO 0-2

Life expectancy

  • Not specified


  • WBC greater than 3,500/mm^3
  • Platelet count greater than 150,000/mm^3
  • Hemoglobin greater than 9.0 g/dL


  • Bilirubin less than 1.5 times normal
  • AST and ALT less than 3.0 times normal


  • Creatinine less than 1.2 mg/dL


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other prior or concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix
  • No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up


Biologic therapy

  • No concurrent immunotherapy


  • No prior chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified


  • No prior radiotherapy


  • See Disease Characteristics
  • Recovered from prior surgery


  • No other concurrent anticancer agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00064207

  Hide Study Locations
Hopital Universitaire Erasme
Brussels, Belgium, 1070
Universitair Ziekenhuis Gent
Ghent, Belgium, B-9000
Hopital de Jolimont
Haine Saint Paul, Belgium, 7100
Cazk Groeninghe - Campus St-Niklaas
Kortrijk, Belgium, B-8500
CHU Liege - Domaine Universitaire du Sart Tilman
Liege, Belgium, B-4000
Algemeen Ziekenhuis Sint-Augustinus
Wilrijk, Belgium, 2610
Centre Hospitalier d'Abbeville
Abbeville, France, 80101
Centre Hospitalier d'Annecy
Annecy, France, 74011 Cedex
Institut Sainte Catherine
Avignon, France, 84082
Hopital Duffaut
Avignon, France, 84902
C.H.G. Beauvais
Beauvais, France, 60021
Centre Hospitalier de Blois
Blois, France, 41016
Clinique Tivoli
Bordeaux, France, F-33000
Polyclinique Bordeaux Nord Aquitaine
Boucher, France, 33300
Centre Hospitalier Universitaire Ambroise Pare - Boulogne
Boulogne Billancourt, France, F-92104
Centre Hospitalier Docteur Duchenne
Boulogne Sur Mer, France, 62200
Centre Hospitalier Pierre Oudot
Bourgoin-Jallieu, France, 38300
CHU de Caen
Caen, France, 14033
CHR Clermont Ferrand, Hotel dieu
Clermont-Ferrand, France, 63003
Hopital Beaujon
Clichy, France, 92118
Louis Mourier Hospital
Colombes Cedex, France, 92701
Centre Hospitalier Universitaire Henri Mondor
Creteil, France, 94010
Centre Hospitalier de Dax
Dax, France, 40107
Hopital Du Bocage
Dijon, France, 21034
Centre Hospitalier Intercommunal St. Aubin les Elbeuf
Elbeuf, France, 76503
CHU de Grenoble - Hopital de la Tronche
Grenoble, France, 38043
Centre Hospitalier Departemental
La Roche Sur Yon, France, F-85025
Clinique Victor Hugo
Le Mans, France, F-72000
Hopital Robert Boulin
Libourne, France, 33500
Centre Hospital Regional Universitaire de Limoges
Limoges, France, 87042
Clinique Saint Jean
Lyon, France, 69008
Centre Leon Berard
Lyon, France, 69373
CHU de la Timone
Marseille, France, 13385
Centre Hospitalier General de Mont de Marsan
Mont-de-Marsan, France, 40000
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Centre Hospitalier de Mulhouse
Mulhouse, France, 68051
C.H.U. de Nimes - Groupe Hospitals-Universitaire Caremeau
Nimes, France, 30029
Hopital Europeen Georges Pompidou
Paris, France, 75015
Hopital Bichat - Claude Bernard
Paris, France, 75018
Hopital Saint Antoine
Paris, France, 75571
CHU Pitie-Salpetriere
Paris, France, 75651
Hopital Cochin
Paris, France, 75674
Hopital Tenon
Paris, France, 75970
C.H.G. De Pau
Pau, France, 64000
Centre Hospitalier Lyon Sud
Pierre Benite, France, 69495
CHU Poitiers
Poitiers, France, 86021
Hopital Charles Nicolle
Rouen, France, 76031
Centre Paul Strauss
Strasbourg, France, 67065
Hopital Universitaire Hautepierre
Strasbourg, France, 67098
Centre Hospitalier Universitaire Bretonneau de Tours
Tours, France, 37044
Centre Alexis Vautrin
Vandoeuvre-les-Nancy, France, 54511
Charite - Campus Charite Mitte
Berlin, Germany, D-10117
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch
Berlin, Germany, D-13122
Universitaetsklinikum Duesseldorf
Duesseldorf, Germany, D-40225
Johannes Gutenberg University
Mainz, Germany, D-55101
Munich Oncologic Practice at Elisenhof
Munich, Germany, D-80335
Rambam Medical Center
Haifa, Israel, 31096
Academisch Medisch Centrum at University of Amsterdam
Amsterdam, Netherlands, 1105 AZ
Hopital Cantonal Universitaire de Geneve
Geneva, Switzerland, CH-1211
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Federation Francophone de Cancerologie Digestive
Study Chair: Jean-Luc Van Laethem, MD, PhD Erasme University Hospital
Study Chair: Volker G. Budach, MD, PhD Charite University, Berlin, Germany
Study Chair: Pascal Hammel, MD, PhD Hopital Beaujon
  More Information

Van Laethem J, Van Cutsem E, Hammel P, et al.: Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer : feasibility results of a randomised EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304). [Abstract] J Clin Oncol 26 (Suppl 15): A-4514, 2008.

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00064207     History of Changes
Other Study ID Numbers: EORTC-40013-22012  EORTC-40013  EORTC-22012  FFCD-0304  EU-20540 
Study First Received: July 8, 2003
Last Updated: September 20, 2012
Health Authority: United States: Federal Government

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
adenocarcinoma of the pancreas
stage I pancreatic cancer
stage II pancreatic cancer
stage III pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on December 09, 2016